A5059704268- Asthma and respiratory diseases
- Eosinophilic Esophagitis
- Respiratory and Cough-Related Research
- Respiratory Support and Mechanisms
- COVID-19 Clinical Research Studies
- Sepsis Diagnosis and Treatment
- Ion Transport and Channel Regulation
- Intensive Care Unit Cognitive Disorders
- Long-Term Effects of COVID-19
- Renal function and acid-base balance
- SARS-CoV-2 and COVID-19 Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Bacterial Identification and Susceptibility Testing
- Allergic Rhinitis and Sensitization
- Biomarkers in Disease Mechanisms
- Antifungal resistance and susceptibility
- Inflammatory Biomarkers in Disease Prognosis
- Cancer, Lipids, and Metabolism
- Inhalation and Respiratory Drug Delivery
- Antibiotic Use and Resistance
Sotiria General Hospital
2019-2024
National and Kapodistrian University of Athens
2022-2023
<b><i>Introduction:</i></b> Mepolizumab is a monoclonal antibody against IL-5 for the treatment of severe eosinophilic asthma. The aim current study was to present predesigned interim analysis data patients who have completed 1 year therapy with mepolizumab. <b><i>Methods:</i></b> This prospective multicenter, noninterventional 2-year observational and aims describe clinical benefit safety profile mepolizumab in...
The impact of severe infection from COVID-19 and the resulting need for life support in an ICU environment is a fact that caused immense pressure healthcare systems around globe. Accordingly, elderly people faced multiple challenges, especially after admission to ICU. On this basis, we performed study assess age on mortality critically ill patients. In retrospective study, collected data 300 patients who were hospitalized Greek respiratory hospital. We split into two groups using threshold...
Remission of asthma can occur as part the natural history disease; however, use biologics result in disease remission some patients.
1. Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126(5):926-938. doi:10.1016/j.jaci.2010.07.019 CrossRef Google Scholar
1. Dimopoulos G, Sakelliou A, Flevari Tzannis K, Giamarellos - Bourboulis J. Ferritin levels in critically ill patients with COVID-19: A marker of outcome? Pneumon. 2021;34(2):5. doi:10.18332/pne/135958 CrossRef Google Scholar
<b>Introduction:</b> Monoclonal antibodies are the pillar of individualized treatment severe asthma. However, there is often phenotypic overlap in patients with asthma, and these may be eligible for more than one available therapies switching between treatments as to achieve best clinical response. <b>Objective:</b> The benefit asthma who, due non-response, switched from omalizumab mepolizumab. <b>Materials-methods:</b> This post-hoc analysis 2-year prospective, multicenter,...
<b>Introduction:</b> Μepolizumab is a monoclonal antibody against IL-5 for the treatment of severe eosinophilic asthma. The aim current study was to present predesigned interim analysis data patients who have completed one year therapy with mepolizumab. <b>Material and Method:</b> This prospective multi-centre, non-interventional 2 -year observational aims describe clinical benefit safety profile mepolizumab in <b>Results:</b> Compared preceding initiation treatment, annual rate...